Letermovir for CMV Prevention After Lung Transplantation

Lung Transplant Clinical Trial

Official title: An Open-label Pilot Protocol to Evaluate the Efficacy of Letermovir for the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Lung Transplant Recipients With Idiopathic Pulmonary Fibrosis

Status Recruiting

Clinical Trial Summary

This is an interventional, open-label, single center, pilot study with historical controls to test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in adult lung transplant recipients (LTRs) with idiopathic pulmonary fibrosis (IPF).

Clinical Trial Description

Approximately 30 patients with IPF listed for lung transplantation will be enrolled and 15 are expected to undergo lung transplantation during the study period and receive the intervention. Patients who are CMV seropositive will receive letermovir for 6 months, patients who are CMV seronegative and receive lungs from a CMV seropositive donor (CMV D+/R-) will receive letermovir for 12 months. All patients will be followed for 12 weeks after completion of letermovir for the occurrence of CMV infection or disease after prophylaxis. Historical controls will be LTRs for IPF from 2010-2019 who are CMV R+ or CMV D+/R- (donor positive/recipient negative). CMV prophylaxis in the historical controls was with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-. Patients will be matched for CMV serostatus, induction immunosuppression, age, and telomere length. ;

Related Conditions & MeSH terms

• CMV
• Lung Transplant

• NCT number: NCT05041426
• Study type: Interventional
• Source: University of Pittsburgh
• Contact: Fernanda Silveira, MD
• Phone: 412-648-6512
• Email: silvfd@upmc.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: December 6, 2021
• Completion date: July 1, 2025